{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:01:16Z","timestamp":1791594076807,"version":"4.3.4"},"reference-count":42,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Childhood Obesity"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>National guidelines support adjunct anti-obesity medications to treat adolescent obesity. The combination of phentermine and topiramate is accessible and efficacious in controlled trials, but very little clinic-based data exist. We sought to describe prescribing characteristics, effectiveness, and safety of phentermine and\/or topiramate in a clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective chart review was conducted among patients prescribed phentermine and\/or topiramate for obesity in a pediatric obesity management program between 2019 and 2021. Patient and provider characteristics, percent BMI change, vital signs, laboratory tests, and discontinuation data were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Patients (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 126) with mean age of 15.5 years, 50% Hispanic, 66% with public insurance, were included, of whom 83% had severe obesity and 51% had \u22653 comorbidities. Discontinuation at 12 months was observed in 58% of the sample, driven primarily by loss to follow-up. Patients who continued medication had significant BMI reductions at 3 (\u22123.1%), 6 (\u22124.7%), 9 (\u22125.2%), and 12 (\u22127.5%) months. Heart rate increased on phentermine by 5\u201310 beats per minute at 9 and 12 months only. Adverse effects were experienced by 25.8% at 3 months and most commonly included mood changes, fatigue, and paresthesias. Side effects and side effect-related discontinuation were most common with topiramate monotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Phentermine and\/or topiramate resulted in BMI reduction in most patients exposed for 3\u201312 months. Safety data support individualized monitoring of heart rate and neuropsychiatric side effects. High attrition and variables associated with differential BMI response require further study. Most patients had severe, complicated obesity at medication initiation and may benefit from earlier intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/chi.2025.0007","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:27:41Z","timestamp":1751434061000},"page":"580-588","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Use of Phentermine and Topiramate for Adolescent Obesity: Retrospective Effectiveness and Safety Analysis"],"prefix":"10.1177","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7656-197X","authenticated-orcid":false,"given":"Courtney E.","family":"Batt","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Academic Pediatrics and Adolescent Medicine, University Hospitals Rainbow Babies and Children\u2019s Hospital, Cleveland, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia C.","family":"Puccio","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital Colorado, University of Colorado, Aurora, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0755-1951","authenticated-orcid":false,"given":"Megan M.","family":"Kelsey","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Endocrinology, Children\u2019s Hospital Colorado, University of Colorado, Aurora, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Boles","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Nutrition, Children\u2019s Hospital Colorado, University of Colorado, Aurora, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime M.","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Nutrition, Children\u2019s Hospital Colorado, University of Colorado, Aurora, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"e_1_3_6_2_2","unstructured":"Centers for Disease Control and Prevention. Childhood Obesity Facts. [Internet]. 2022. [cited 2023 Aug 4]. Available from: https:\/\/www.cdc.gov\/obesity\/data\/childhood.html#:\u223c:text=Prevalence%20of%20Childhood%20Obesity%20in%20the%20United%20States&text=Obesity%20prevalence%20among%20children%20and 14.7%20million%20children%20and%20adolescents"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-3459"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3060"},{"issue":"2","key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"e2021053708","DOI":"10.1542\/peds.2021-053708","article-title":"Changes in the incidence of childhood obesity","volume":"150","author":"Cunningham SA","year":"2022","unstructured":"Cunningham SA, , Hardy ST, , Jones R, et al. Changes in the incidence of childhood obesity. Pediatrics, 2022; 150(2):e2021053708.","journal-title":"Pediatrics"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060640"},{"issue":"25","key":"e_1_3_6_7_2","first-page":"2985","article-title":"AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"63","author":"Jensen MD","year":"2014","unstructured":"Jensen MD, , Ryan DH, , Apovian CM, et al. AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol, 20142014;63(25):2985\u20133023.","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/chi.2013.0120"},{"issue":"5","key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report","volume":"128","author":"EXPERT PANEL ON INTEGRATED GUIDELINES FOR CARDIOVASCULAR HEALTH AND RISK REDUCTION IN CHILDREN AND ADOLESCENTS","year":"2011","unstructured":"EXPERT PANEL ON INTEGRATED GUIDELINES FOR CARDIOVASCULAR HEALTH AND RISK REDUCTION IN CHILDREN AND ADOLESCENTS. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. PEDIATRICS, 2011; 128(Supplement_5):S213\u2013S256.","journal-title":"PEDIATRICS"},{"issue":"12","key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/2013.jamapediatrics.319","article-title":"Response of severely obese children and adolescents to behavioral treatment","volume":"166","author":"Danielsson P","year":"2012","unstructured":"Danielsson P, , Kowalski J, , Ekblom \u00d6, et al. Response of severely obese children and adolescents to behavioral treatment. Arch Pediatr Adolesc Med, 2012; 166(12):1103\u20131108.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.2047-6310.2013.00212.x","article-title":"Extremely obese children respond better than extremely obese adolescents to lifestyle interventions","volume":"10","author":"Knop C","year":"2015","unstructured":"Knop C, , Singer V, , Uysal Y, et al. Extremely obese children respond better than extremely obese adolescents to lifestyle interventions. Pediatr Obes, 2015; 10(1):7\u201314.","journal-title":"Pediatr Obes"},{"key":"e_1_3_6_12_2","unstructured":"Centers for Disease Control and Prevention. CDC-Recognized Family Healthy Weight Programs [Internet]. 2024. [cited 2024 Oct 21]. Available from: https:\/\/www.cdc.gov\/family-healthy-weight\/php\/recognized-programs\/index.html"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813909"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506699"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.7602"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281361"},{"issue":"6","key":"e_1_3_6_17_2","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200014","article-title":"Phentermine\/topiramate for the treatment of adolescent obesity","volume":"1","author":"Kelly AS","year":"2022","unstructured":"Kelly AS, , Bensignor MO, , Hsia DS, et al. Phentermine\/topiramate for the treatment of adolescent obesity. NEJM Evid, 2022; 1(6); doi: 10.1056\/evidoa2200014","journal-title":"NEJM Evid"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/chi.2022.0147"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/chi.2022.0062"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2009.10.001"},{"issue":"2","key":"e_1_3_6_21_2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1212\/WNL.52.2.321","article-title":"Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults","volume":"52","author":"Martin R","year":"1999","unstructured":"Martin R, , Kuzniecky R, , Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology, 1999; 52(2):321\u2013327.","journal-title":"Neurology"},{"issue":"1","key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s11096-021-01330-2","article-title":"Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013\u20132020","volume":"44","author":"Alsuhibani A","year":"2022","unstructured":"Alsuhibani A, , Alrasheed M, , Gari M, et al. Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013\u20132020. Int J Clin Pharm, 2022; 44(1):172\u2013179.","journal-title":"Int J Clin Pharm"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208601"},{"issue":"8","key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"e13143","DOI":"10.1111\/ijpo.13143","article-title":"Effectiveness and predictors of weight loss response to phentermine plus lifestyle modifications among youth in a paediatric weight management clinical setting","volume":"19","author":"Bomberg EM","year":"2024","unstructured":"Bomberg EM, , Clark J, , Rudser KD, et al. Effectiveness and predictors of weight loss response to phentermine plus lifestyle modifications among youth in a paediatric weight management clinical setting. Pediatr Obes, 2024; 19(8):e13143.","journal-title":"Pediatr Obes"},{"issue":"3","key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"bvac195","DOI":"10.1210\/jendso\/bvac195","article-title":"An updated approach to antiobesity pharmacotherapy: Moving beyond the 5% weight loss goal","volume":"7","author":"Enright C","year":"2023","unstructured":"Enright C, , Thomas E, , Saxon DR. An updated approach to antiobesity pharmacotherapy: Moving beyond the 5% weight loss goal. J Endocr Soc, 2023; 7(3):bvac195.","journal-title":"J Endocr Soc"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab276"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.4221"},{"issue":"16","key":"e_1_3_6_28_2","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jama.2023.4855","article-title":"Randomized trials vs real-world evidence: How can both inform decision-making","volume":"329","author":"Sheldrick RC","year":"2023","unstructured":"Sheldrick RC. Randomized trials vs real-world evidence: How can both inform decision-making? JAMA, 2023; 329(16):1352\u20131353.","journal-title":"JAMA"},{"issue":"5","key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"e20184112","DOI":"10.1542\/peds.2018-4112","article-title":"Intellectual disability and adolescent bariatric surgery: Support of special eligibility criteria","volume":"143","author":"Michalsky MP","year":"2019","unstructured":"Michalsky MP. Intellectual disability and adolescent bariatric surgery: Support of special eligibility criteria. Pediatrics, 2019; 143(5):e20184112.","journal-title":"Pediatrics"},{"issue":"3","key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.dhjo.2015.12.003","article-title":"Intellectual disability is associated with increased risk for obesity in a nationally representative sample of U.S. children","volume":"9","author":"Segal M","year":"2016","unstructured":"Segal M, , Eliasziw M, , Phillips S, et al. Intellectual disability is associated with increased risk for obesity in a nationally representative sample of U.S. children. Disabil Health J, 2016; 9(3):392\u2013398.","journal-title":"Disabil Health J"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.112.1.155"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0258(20000715)19:13<1793::AID-SIM482>3.0.CO;2-Q"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21633"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/0009922814542481"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2016.185"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.6803"},{"issue":"4","key":"e_1_3_6_37_2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/00325481.2022.2051366","article-title":"What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review","volume":"134","author":"Horn DB","year":"2022","unstructured":"Horn DB, , Almandoz JP, , Look M. What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. Postgrad Med, 2022; 134(4):359\u2013375.","journal-title":"Postgrad Med"},{"issue":"9","key":"e_1_3_6_38_2","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41574-023-00858-9","article-title":"Current and future pharmacotherapies for obesity in children and adolescents","volume":"19","author":"Kelly AS","year":"2023","unstructured":"Kelly AS. Current and future pharmacotherapies for obesity in children and adolescents. Nat Rev Endocrinol, 2023; 19(9):534\u2013541.","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"e_1_3_6_39_2","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/oby.2011.94","article-title":"Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity","volume":"19","author":"Hendricks EJ","year":"2011","unstructured":"Hendricks EJ, , Greenway FL, , Westman EC, et al. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring), 2011; 19(12):2351\u20132360.","journal-title":"Obesity (Silver Spring)"},{"key":"e_1_3_6_40_2","doi-asserted-by":"crossref","first-page":"1369270","DOI":"10.3389\/fendo.2024.1369270","article-title":"Clinical effectiveness and predictors of response to topiramate plus lifestyle modification in youth with obesity seen in a weight management clinical setting","volume":"15","author":"Bomberg EM","year":"2024","unstructured":"Bomberg EM, , Clark J, , Rudser KD, et al. Clinical effectiveness and predictors of response to topiramate plus lifestyle modification in youth with obesity seen in a weight management clinical setting. Front Endocrinol (Lausanne), 2024; 15:1369270.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2010.00803.x"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1177\/0009922811410876"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15036"}],"container-title":["Childhood Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/chi.2025.0007","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/chi.2025.0007","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/chi.2025.0007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:24:09Z","timestamp":1779877449000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/chi.2025.0007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10,1]]}},"alternative-id":["10.1089\/chi.2025.0007"],"URL":"https:\/\/doi.org\/10.1089\/chi.2025.0007","relation":{},"ISSN":["2153-2168","2153-2176"],"issn-type":[{"value":"2153-2168","type":"print"},{"value":"2153-2176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]}}}